Fairvalue-Calculator Fairvalue-Calculator
EN DE

Pulmonx Corporation (LUNG) Fair Value & Analysis

Healthcare · US · Market cap $54.1M

Price$1.39
Fair Value$7.09
Upside+410.1%
Quality95/100
Evidence: Low Range $3.94 – $9.76

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Pulmonx Corporation (LUNG) currently trades at $1.39, while our model-based Fair Value estimate is $7.09 — implying the stock looks roughly 410.1% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and international…

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -9% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -5% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is Pulmonx Corporation (LUNG) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $7.09 versus a price of $1.39 — about +410% (undervalued). Model-based estimate, not financial advice.
What is the fair value of LUNG?
Our 21-model fair value for Pulmonx Corporation is $7.09 (as of Jun 25, 2026), built from audited fundamentals. The current price is $1.39.
What is the quality score of LUNG?
Pulmonx Corporation has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.